Understanding how melanoma cells resist treatment without genetic changes
Mechanisms of non-genetic variation in melanoma
This study is looking at how some melanoma cells can survive treatment and what makes them resistant, so we can find better ways to help melanoma patients respond to therapy.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10903804 on NIH RePORTER |
What this research studies
This research investigates the non-genetic mechanisms that allow melanoma cells to resist therapy, particularly after initial treatments that target the MAPK pathway. It focuses on identifying rare cells within tumors that exhibit high resistance levels and understanding the genetic pathways and enhancers that contribute to this resistance. By characterizing these mechanisms, the research aims to find new pharmacologic targets that could help prevent therapy resistance in melanoma patients. This work is being conducted at Yale University under the mentorship of a leading expert in gene regulation in cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who have experienced treatment failure despite initial success.
Not a fit: Patients with melanoma who have not undergone treatment or those with early-stage melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that prevent melanoma from becoming resistant to therapy, improving patient outcomes.
How similar studies have performed: Other research has shown promise in understanding therapy resistance in various cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Garg, Salil — Yale University
- Study coordinator: Garg, Salil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.